Clinical Trials · NCT05884255
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Enrollment
- 220
- Start date
- Jul 2023
- Locations
- 2 sites, China
- Primary endpoint
- Progression-free survival (PFS) assessed by BICR